Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Adimmune Corporation (4142.TW)
TWD17.45
+0.60 (+3.56%)
TW TAI Healthcare Biotechnology
Address
No. 3, Tanxing Road 427003
Taichung, TW
Taichung, TW
CEO
Chi-Hsien Chan
Website
adimmune.com.tw
IPO
2012-05-03
ISIN TW0004142005
Description
Adimmune Corporation, a Taiwanese pharmaceutical company, specializes in the production and distribution of human vaccines. Its comprehensive product portfolio includes a range of critical immunizations. Key offerings feature the quadrivalent influenza vaccine, AdimFlu-S, alongside trivalent influenza vaccines and the Influenza A (H1N1) Virus Monovalent Vaccine. The company also provides tetanus toxoid products, vital for post-injury tetanus prevention, and Japanese encephalitis vaccines. Furthermore, Adimmune supplies purified Tuberculin and extends its expertise through contract manufacturing services. Established in 1965, the company initially operated under the name Kuo Kwang Serum and Vaccine Manufacture Co., Ltd. It subsequently rebranded as Adimmune Corporation in 2001 and maintains its headquarters in Taichung, Taiwan.
Market Cap & Enterprise Value
Merger & Acquisition History
No mergers or acquisitions recorded for this company.
Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary
Loading…
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
TWD17.45
+0.60 (+3.56%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
1M
Beta
0.28
Float Shares
347.20M
Free Float %
82.4%
Price Performance
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -1.42% | -2.80% | -6.22% | -3.88% | -14.53% | -8.44% | -10.57% | -53.49% | -69.98% | -19.84% | -53.14% |
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From
To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
Loading histogram data…
Revenue flow
Revenue by geography
Revenue by segment
From
To
Revenue composition
From
To
By product
By geography
Financial Statements
Select metrics from the tables below to build your comparison.
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
Price Targets & DCF
Current price
17.45
Ratings Trend (MoM)
100% Bullish
| Rating | 2025-03 | Change |
|---|---|---|
| Strong Buy | 1 | 0 |
| Buy | 0 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
Quality scores
Altman Z-Score
1.72
Distress
Piotroski F-Score
3 / 9
Average
MOAT Score
0 / 10
No MOAT
Composite Rating
C
Overall Score
2 / 5
Medium
DCF Score
1 / 5
Low
ROE Score
1 / 5
Low
ROA Score
1 / 5
Low
D/E Score
2 / 5
Medium
P/E Score
1 / 5
Low
P/Book Score
4 / 5
High
Operational MOAT
✗ Below peers
-
Revenue growth Biotechnology: +1.6%-10.0% Q1'26: +14.2% (vs Q1'25)
-
EPS growth Biotechnology: +29.7%+1.7% Q1'26: +17.0% (vs Q1'25)
-
FCF margin FCF growth · Biotechnology: +16.2%-23.0% Q1'26: -337.3% (vs Q1'25)
-
EBIT margin Biotechnology: +0.0%-25.7% Q1'26: -242.0% (vs Q1'25)
-
ROIC Biotechnology: -16.1%-6.4% ★ Q1'26: -13.9% (vs Q1'25)
-
Share dilution Biotechnology: -3.4%-0.2% ★ Q1'26: +0.0% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Biotechnology: 0.16×-19.56× Q1'26: -4.58× (vs Q1'25)
Valuation Multiples
From
To
Price Forecast (3Y)
From
To
Theoretical Return — If Invested Today
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
Consensus Estimates
| Metric |
Dec 2015 actual |
Dec 2016 actual |
Dec 2017 actual |
Dec 2019 actual |
Dec 2020 actual |
Dec 2021 actual |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 1 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
290.74M
est: 307.00M (-5.3%)
|
606.73M
est: 607.00M (0.0%)
|
562.74M
est: 909.00M (-38.1%)
|
1.30B
est: 1.30B (0.0%)
|
1.87B
est: 2.46B (-24.2%)
|
1.64B
est: 1.75B (-6.2%)
|
2.25B
est: 2.34B (-3.6%)
|
1.79B
est: 2.72B (-34.5%)
|
1.56B
est: 1.69B (-8.0%)
|
1.40B
est: 1.71B (-18.0%)
|
1.78B
1.78B – 1.78B
+3.9% YoY
|
| EBITDA |
-400.02M
est: 48.07M (-932.2%)
|
-302.29M
est: 95.04M (-418.1%)
|
-445.84M
est: 142.32M (-413.3%)
|
-33.32M
est: 203.54M (-116.4%)
|
1.45B
est: 385.87M (+275.0%)
|
254.89M
est: 274.00M (-7.0%)
|
438.12M
est: 365.59M (+19.8%)
|
-512.43M
est: 426.50M (-220.1%)
|
-84.30M
est: -31.99M (-163.5%)
|
-144.69M
est: -32.32M (-347.7%)
|
-33.56M
-33.56M – -33.56M
-3.9% YoY
|
| EBIT |
-705.23M
est: 8.85M (-8,066.7%)
|
-594.04M
est: 17.50M (-3,494.0%)
|
-737.69M
est: 26.21M (-2,914.5%)
|
-273.53M
est: 37.48M (-829.7%)
|
1.22B
est: 71.06M (+1,616.0%)
|
28.97M
est: 50.46M (-42.6%)
|
178.81M
est: 67.33M (+165.6%)
|
-736.55M
est: 78.55M (-1,037.7%)
|
-300.00M
est: -258.80M (-15.9%)
|
-359.55M
est: -261.40M (-37.5%)
|
-271.49M
-271.49M – -271.49M
-3.9% YoY
|
| Net Income |
-761.09M
est: -940.38M (+19.1%)
|
-595.35M
est: -844.34M (+29.5%)
|
-760.18M
est: -524.21M (-45.0%)
|
-280.68M
est: -231.83M (-21.1%)
|
1.24B
est: 1.30B (-4.2%)
|
43.07M
est: 606.97M (-92.9%)
|
290.98M
est: 295.06M (-1.4%)
|
-639.89M
est: 278.20M (-330.0%)
|
-242.75M
est: -101.01M (-140.3%)
|
-239.89M
est: -21.04M (-1,040.0%)
|
-16.83M
-16.83M – -16.83M
+20.0% YoY
|
| SGA |
241.64M
est: 68.65M (+252.0%)
|
238.52M
est: 135.74M (+75.7%)
|
221.66M
est: 203.27M (+9.0%)
|
230.93M
est: 290.70M (-20.6%)
|
311.19M
est: 551.10M (-43.5%)
|
349.67M
est: 391.33M (-10.6%)
|
446.11M
est: 522.15M (-14.6%)
|
442.87M
est: 609.13M (-27.3%)
|
455.11M
est: 409.54M (+11.1%)
|
362.48M
est: 413.66M (-12.4%)
|
429.63M
429.63M – 429.63M
+3.9% YoY
|
| EPS |
-3.08
est: -2.23 (-38.1%)
|
-2.41
est: -2.00 (-20.3%)
|
-3.07
est: -1.24 (-146.9%)
|
-0.77
est: -0.55 (-40.0%)
|
3.03
est: 3.08 (-1.5%)
|
0.10
est: 1.44 (-93.1%)
|
0.68
est: 0.70 (-2.9%)
|
-1.52
est: 0.66 (-330.3%)
|
-0.58
est: -0.24 (-141.7%)
|
-0.57
est: -0.05 (-1,040.0%)
|
-0.04
-0.04 – -0.04
+20.0% YoY
|
Historical Ratings (3M)
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-19 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-05-18 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-05-15 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-05-14 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-05-13 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-05-12 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-05-11 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-05-08 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-05-07 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-05-06 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-05-05 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-05-04 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-30 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-29 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-28 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-27 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-24 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-23 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-22 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-21 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-20 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-17 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-16 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
Owner Earnings
Owner's Earnings (history)
From
To
Owner alignment
Owner's Earnings TTM
-1.13B
OE per share TTM
-2.45
Owner's Yield
-15.24%
Maintenance CapEx ratio
—
Maint CapEx / Avg PPE
197.0%
Ownership Overview
Ownership breakdown
Ownership breakdown not available.
At a glance
Institutional holders
—
Total invested
—
Insider transactions (90d)
0
Beneficial owners (>5%)
0
Beneficial owners (>5%)
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional ownership trend
Institutional history not available.
Top institutional holders
Top holders not available.
ETF Ownership
Top ETFs holding this stock
Held by 23 ETFs in our universe
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | Avantis Emerging Markets Small Cap Equity ETF AVEE | 0.01% | 14.9K | 0.42% |
| 2 | Vanguard FTSE All-World ex-US Small-Cap ETF VSS | 0.00% | 582.7K | 0.06% |
| 3 | Dimensional - Emerging Markets Core Equity 2 ETF DFEM | 0.00% | 244.7K | 0.39% |
| 4 | Dimensional - Emerging Core Equity Market ETF DFAE | 0.00% | 171.8K | 0.29% |
| 5 | State Street SPDR Portfolio Emerging Markets ETF SPEM | 0.00% | 297.1K | 0.07% |
| 6 | Vanguard FTSE Emerging Markets All Cap Index ETF VEE.TO | 0.00% | 45.0K | 0.26% |
| 7 | Vanguard FTSE Emerging Markets Shares ETF VGE.AX | 0.00% | 19.9K | 0.48% |
| 8 | Vanguard FTSE Emerging Markets ETF VWO | 0.00% | 2.22M | 0.06% |
| 9 | Avantis Emerging Markets Equity UCITS ETF USD Acc AVEM.L | 0.00% | 3.2K | 0.35% |
| 10 | Dimensional - Emerging Markets ex China Core Equity ETF DEXC | 0.00% | 3.9K | 0.56% |
Insider Activity
Insider Activity — Latest Quarter
No insider activity available.
Insider buys vs sells (history)
Insider history not available.
Recent insider transactions
No recent insider transactions.
Executive team
Top executives
EBIT / Employee
-637.5K
Shares Outstanding
421.51M
Executive compensation
Executive compensation (annual)
Executive compensation not available.
CEO compensation breakdown
No CEO compensation history available.
Proxy statements
Proxy statements (DEF 14A)
No proxy statements available for this company yet.
Recent SEC filings
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Chi-Hsien Chan | Chief Executive Officer & Chairman | 24M | male |
| Chin-Chuan Chang | Chief Operating Officer and Vice President of R&D | 5M | male |
| Fei Pan | Chief Legal Officer & General Counsel | 5M | male |
| Chin-I Chiu | Vice President of Quality Assurance Department | 5M | male |
| Zhe Wei Zhang | Executive Vice GM | — | — |
| Chih-Hsiang Leng | Head of R&D Division | — | — |
| Li-Ya Tang | Director of Administration Center | — | female |
| Cheng Liu Churg | Acting R&D Officer | — | — |
ESG Score History
No data available for this company.
Senate Trading Activity
No Senate trading activity found for this company.
House Trading Activity
No House trading activity found for this company.
Market share among peers
Peer comparison — filtered group (TTM)
Your opinion
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for 4142.TW
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
